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Abstract
Epithelioid hemangioendothelioma is an extremely rare vascular neoplasm arising in soft-tissues and different visceral organs, with liver being 
the most commonly involved viscera. Hepatic epithelioid hemangioendothelioma (HEHE) is a malignant tumour with an indolent behaviour 
and unpredictable clinical course. It has a better prognosis among the malignant tumours of the liver, in spite of being a diffuse multifocal liver 
disease or metastatic at the time of presentation. HEHE is usually found to be noted in the fifth decade with slight female preponderance. No 
single treatment strategy has yet been established owing to its variable clinical course, ranging from an indolent tumour with prolonged survival 
to an aggressive, metastatic disease with a fatal outcome. Here, we present a case of a novel HEHE in a 25-year-old female who was treated suc-
cessfully with orthotopic living donor liver transplantation and discuss the presentation, histopathology and management of this rare, fatal yet 
treatable malignant tumour. 
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Case Summary
A 25-year-old female presented with complaints of right-
sided upper quadrant pain on and off  for the last 1 year 
associated with significant weight loss. Her blood investiga-
tions were normal except for mild increase in transaminases 
[SGOT & SGPT]. Rest of her liver function tests were 
within normal limits. Abdominal ultrasonogram followed 
by Doppler was done which showed a coarse echotexture 
of the liver with multiple heteroechoic lesions with coales-
cence seen in periportal and sub-pleural regions, the largest 
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lesion measuring 10.7 × 14.4 cm. Portal and hepatic veins 
were patent. CT of the abdomen was done which revealed 
a liver with heterogeneous density and multifocal confluent 
hypodense areas along the subscapular region and along the 
portal vein branches. Lesions were seen predominantly in the 
right lobe and scattered across segments VIII, V, VII, IVA 
and IVB. The largest lesion in periportal region extending to 
left lobe measuring 9.8 × 6.9cm. Post-contrast study showed 
heterogeneous enhancement of lesions with no calcifications 
within [Figure 1]. Image-guided biopsy of the liver lesion was 
done which was suggestive of Hepatic Epitheloid Heman-
gio Endothelioma [HEHE]. She was evaluated further and 
was advised to undergo liver transplantation. Her maternal 
uncle came forward to donate a part of his liver and after 
complete evaluation and risk assessment, he was cleared to 
donate his right lobe. Right lobe without middle hepatic vein 
was harvested from the donor. The anterior sector outflow 
was reconstructed using 10-mm PTFE [Poly Tetra Fluoro 
Ethylene] graft and the graft was implanted. 
Her explant liver weighed 1356 g measuring 22 × 15 × 
9 cm, with right lobe measuring 11 × 15 x 9 cm and left lobe 
12 × 11 × 7 cm. On slicing, multifocal tumour involving both 
right and left lobe was identified with largest tumour in right 
lobe measuring 8 × 7 cm and largest in left lobe measuring 7 
× 5 cm. Smaller tumour nodules were also noted  [Figure 2]. 
The tumour was infiltrative, firm and greyish-white with 
indistinct margins and yellowish areas of necrosis. Non- 
tumoral liver showed patchy congestion. The tumour was 
involving vessels and was infiltrating hilar connective tissue 
grossly. The sections showed a multifocal diffusely infiltrat-
ing tumour with round to polygonal tumour embedded in 
fibromyxoid stroma. The tumour cells are arranged singly, in 
cords and also in clusters and tuft in sinusoids and  vessels. 
Multinucleation was noted. The tumour cells show high 
nucleocytoplasmic ratio and pleomorphic hyperchromatic 
nuclei with variable eosinophilic cytoplasm. Small nucleoli 
and cytoplasmic vacuolisation were noted. Areas of necrosis 
and admixed inflammation comprising of lymphocytes, his-
tiocytes and polymorphs were present. Diffuse infiltration of 
hepatic vessels with luminal obliteration along with tumour 
infiltration in portal areas were seen. Entrapped nerve bun-
dles were noted. There non-tumoral liver showed areas of 
sinusoidal dilatation, congestion and hepatocyte atrophy and 
hepatocyte dropout. Regenerative changes of hepatocyte 
plates are noted. The final impression was that of multifocal 
hepatic epithelioid hemangioendothelioma. Immunohisto-
chemistry was done and cells were strongly positive for CD34 
[Figure 3] with positive FLI1, D2-40 and patchy mild posi-
tive for PAN-CK. TFE-3 nuclear expression was suggestive 
of TF3-YAP1 fusion [Figure 4].
She recovered well and was discharged from the hospital 
on eighth post-operative day. She was started on tacrolimus, 
mycophenolate mofetil and steroids for immunosuppression 
titrated against the lower limit of the recommended tacroli-
mus trough levels, and has been on regular follow-up with no 
recurrence till date.
Introduction
Epitheloid hemangioendothelioma (EHE) was first described 
in soft tissues by Weiss and Enzinger about four decades ago. 
Since then, EHE has been reported in other organs such as 
Figure 1: Post-contrast study showed heterogeneous enhancement of lesions with no calcifications.
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lungs, liver, mediastinum and bone (1). Ishak reported the 
first Hepatic epitheloid hemangioendothelioma (HEHE) in 
1984, while he was studying the clinical and morphologic fea-
tures of HEHE in a series evaluating 32 patients. HEHE is a 
rare vascular tumour with an incidence rate of 1 in 100,000 
originating from endothelial cells; however, it resembles an 
epithelioid neoplasm. Usually noted in the fifth decade with 
slight female preponderance with a female-to-male ratio 
of 3:2 (2). Factors predisposing to HEHE have not been 
well-defined; however, prolonged usage of oral contraceptive 
pills, hepatitis B infection, alcohol abuse, primary biliary cir-
rhosis and exposure to vinyl chloride, polyurethane, silicone, 
asbestos and thorotrast are postulated to be the possible risk 
factors (3).
Usually detected incidentally on imaging studies, since the 
presenting clinical symptoms, signs and laboratory findings 
are non-specific (4). The most common presenting features 
among symptomatic patients are right upper quadrant pain, 
hepatomegaly and weight loss. These features are more pro-
nounced when they develop features of portal hypertension, 
Budd–Chiari syndrome or hepatic failure (5).
All the routine tumour markers namely carcinoembry-
onic antigen (CEA), CA19-9 and alpha-fetoprotein are usu-
ally not elevated (6). Rarely, it can be solitary, but majority 
cases are multicentric with bilobar involvement of both 
liver lobes  (3). The lesions start as small discrete nodules 
commonly located at the periphery and invades the capsule. 
These nodules gradually grow in size, coalesce to form com-
plex confluent masses. Contrast-enhanced CT shows lesions 
with a low attenuating centre surrounded by a peripheral rim 
of enhancement. MRI shows similar features (7). Retraction 
or flattening of the liver capsule secondary to fibrosis is a 
characteristic finding in HEHE. In the arterial phase, some 
of the lesions demonstrate a mild homogeneous enhance-
ment which does not increase in the portal venous or delayed 
phases. Some lesions show a ring-like arterial phase enhance-
ment followed by a central filling on the portal venous and 
delayed phases, the characteristic “halo sign.” Few lesions 
have heterogeneous enhancement pattern that progresses 
during the portal and delayed phases. The enhancement pat-
tern appears to be directly proportional to the tumour size; 
with lesions more than 3 cm showing a delayed heteroge-
neous enhancement, lesions less than 2 cm showing homoge-
nous enhancement and 2–3-cm-sized tumours exhibiting the 
halo sign that is, ring-like enhancement (8).
Alomari described the characteristic “Lollipop” sign on 
either contrast-enhanced CT or MRI which is more specific 
to HEHE than the halo sign. The HEHE infiltrates sinusoids, 
venules and veins causing narrowing of these structures 
which resembles the stick of a lollipop ending in a well-de-
fined tumour resembling the candy (9). One-fourth of the 
lesions might have intra-tumoral calcification, which when 
present, is a very helpful diagnostic feature. Mehrabi et  al 
Figure 2: Smaller tumour nodules were also noted.
(B)
(A)
Figure 3: Immunohisto-chemistry showing cells strongly 
 positive for CD34.
Figure 4: TFE-3 nuclear expression was suggestive of 
TF3-YAP1 fusion.
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Although HEHE is supposed to be a malignant and 
probably aggressive hepatic vascular tumour with the risk 
of recurrence post-immunosuppression, with just adequate 
immunosuppression, careful close monitoring and strict 
post-operative vigilance, liver transplantation can serve to be 
an ultimate cure for HEHEs. 
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Fortunately, even the HEHE with extra-hepatic spread at 
the time of diagnosis have favourable outcomes and good 
long-term disease-free survival rates after liver transplanta-
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with ill-defined nodules that are firm in consistency and a 
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